Evidence map›Paper›PMID 29535553›Full record

ArticleCancer management and research2018

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?

Bibi Kulsoom, Tahir Sultan Shamsi, Nasir Ali Afsar, Zahida Memon, Nikhat Ahmed, Syed Nazrul Hasnain

Open access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 143 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Mechanistic insights intoJournal of advanced veterinary and animal research · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Roles of Sirtuins in Hearing Protection.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Bibi KulsoomNational Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan.
Tahir Sultan ShamsiNational Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan.
Nasir Ali AfsarJinnah Medical and Dental College, Karachi, Pakistan.
Zahida MemonZiauddin University, Karachi, Pakistan.
Nikhat AhmedZiauddin University, Karachi, Pakistan.
Syed Nazrul HasnainDow International Medical College, Karachi, Pakistan.
National Institute Of Blood Disease and Bone Marrow Transplantation · PKZiauddin University · PKAlfaisal University · SADow University of Health Sciences · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMany anticancer drugs induce apoptosis in malignant cells, and resistance to apoptosis could lead to suboptimal or no therapeutic benefit. Two cytoplasmic proteins, B-cell lymphoma protein 2 (Bcl-2)-associated X (Bax) and Bcl-2, act as a promoter and an inhibitor of apoptosis, respectively. Both Bax and Bcl-2 as well as their ratio have been regarded as prognostic markers in various cancers. However, conflicting results have been reported. A clear understanding of apoptosis has also become crucial due to reports about anti-Bcl-2 chemotherapy. We explored the relationship of Bax and Bcl-2 gene expression and their ratio with the therapeutic response in acute myeloid leukemia (AML) patients. PATIENTS AND

methodsBone marrow and/or blood samples from 90 AML patients treated with cytarabine and daunorubicin were included. Expression of Bax and Bcl-2 was determined through real-time polymerase chain reaction by using ΔΔCt method of relative expression.

resultsBax and Bcl-2 expression among marrow and blood samples correlated with each other (

conclusionExpression of Bax and Bcl-2 does not differ significantly among AML patients treated with cytarabine and daunorubicin in terms of remission, relapse, resistance, overall survival, and disease-free survival, thus questioning the utility of emerging anti-Bcl-2 therapy.

Indexed as

anthracyclinesanti Bcl-2 therapyBax Bcl-2 ratioBcl-2BH3 mimetic inhibitorscytarabine

Identifiers

PMID29535553
PMCPMC5841349
OpenAlexW2791139215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.